Sex differences in transplantation

Transplantation Reviews

Volumn 31, Issue 3, 2017, Pages 145-150

  Momper, Jeremiah D ^a   Misel, Michael L ^b   McKay, Dianne B ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO HEALTH SYSTEM   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYTOCHROME P450 3A; GLUCOCORTICOID; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 2; MYCOPHENOLIC ACID; PREDNISONE; TACROLIMUS; ANTIINFECTIVE AGENT; IMMUNOSUPPRESSIVE AGENT;

BK VIRUS INFECTION; CLINICAL RESEARCH; CYTOMEGALOVIRUS INFECTION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG METABOLISM; DRUG USE; GENDER; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; NONHUMAN; PATIENT CARE; REVIEW; SEX DIFFERENCE; TRANSPLANTATION; FEMALE; MALE; ORGAN TRANSPLANTATION; SEX FACTOR;

ANTI-INFECTIVE AGENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; ORGAN TRANSPLANTATION; SEX FACTORS;

EID: 85014081707     PISSN: 0955470X     EISSN: 15579816     Source Type: Journal    
DOI: 10.1016/j.trre.2017.02.003     Document Type: Review

References (81)

1. Clayton, J.A., Collins, F.S., Policy: NIH to balance sex in cell and animal studies. Nature 509 (2014), 282–283.
2. Kang, D.H., Yu, E.S., Yoon, K.I., Johnson, R., The impact of gender on progression of renal disease: potential role of estrogen-mediated vascular endothelial growth factor regulation and vascular protection. Am J Pathol 164 (2004), 679–688.
3. Neugarten, J., Acharya, A., Silbiger, S.R., Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol 11 (2000), 319–329.
4. Baylis, C., Renal effects of cyclooxygenase inhibition in the pregnant rat. Am J Physiol 253 (1987), F158–F163.
5. Baylis, C., Wilson, C.B., Sex and the single kidney. Am J Kidney Dis 13 (1989), 290–298.
6. Munger, K., Baylis, C., Sex differences in renal hemodynamics in rats. Am J Physiol 254 (1988), F223–F231.
7. Ellison, K.E., Ingelfinger, J.R., Pivor, M., Dzau, V.J., Androgen regulation of rat renal angiotensinogen messenger RNA expression. J Clin Invest 83 (1989), 1941–1945.
8. Silbiger, S.R., Raging hormones: gender and renal disease. Kidney Int 79 (2011), 382–384.
9. Meier-Kriesche, H.U., Ojo, A.O., Leavey, S.F., et al. Gender differences in the risk for chronic renal allograft failure. Transplantation 71 (2001), 429–432.
10. Smith, J.M., Martz, K., Blydt-Hansen, T.D., Pediatric kidney transplant practice patterns and outcome benchmarks, 1987-2010: a report of the north American pediatric renal trials and collaborative studies. Pediatr Transplant 17 (2013), 149–157.
11. Bobanga, I.D., Vogt, B.A., Woodside, K.J., et al. Outcome differences between young children and adolescents undergoing kidney transplantation. J Pediatr Surg 50 (2015), 996–999.
12. Muller, V., Szabo, A., Viklicky, O., et al. Sex hormones and gender-related differences: their influence on chronic renal allograft rejection. Kidney Int 55 (1999), 2011–2020.
13. Barbarino, J.M., Staatz, C.E., Venkataramanan, R., Klein, T.E., Altman, R.B., PharmGKB summary: cyclosporine and tacrolimus pathways. Pharmacogenet Genomics 23 (2013), 563–585.
14. Tornatore, K.M., Brazeau, D., Dole, K., et al. Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients. J Clin Pharmacol 53 (2013), 1039–1047.
15. Christians, U., Jacobsen, W., Benet, L.Z., Lampen, A., Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41 (2002), 813–851.
16. Hochleitner, B.W., Bosmuller, C., Nehoda, H., et al. Increased tacrolimus levels during diarrhea. Transpl Int 14 (2001), 230–233.
17. Staatz, C.E., Goodman, L.K., Tett, S.E., Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part II. Clin Pharmacokinet 49 (2010), 207–221.
18. Staatz, C.E., Goodman, L.K., Tett, S.E., Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 49 (2010), 141–175.
19. Kahan, B.D., Kramer, W.G., Wideman, C., Flechner, S.M., Lorber, M.I., Van Buren, C.T., Demographic factors affecting the pharmacokinetics of cyclosporine estimated by radioimmunoassay. Transplantation 41 (1986), 459–464.
20. Bleck, J.S., Thiesemann, C., Kliem, V., et al. Diltiazem increases blood concentrations of cyclized cyclosporine metabolites resulting in different cyclosporine metabolite patterns in stable male and female renal allograft recipients. Br J Clin Pharmacol 41 (1996), 551–556.
21. Schroeder, T.J., Cho, M.J., Pollack, G.M., et al. Comparison of two cyclosporine formulations in healthy volunteers: bioequivalence of the new sang-35 formulation and Neoral. J Clin Pharmacol 38 (1998), 807–814.
22. Velickovic-Radovanovic, R., Mikov, M., Paunovic, G., et al. Gender differences in pharmacokinetics of tacrolimus and their clinical significance in kidney transplant recipients. Gend Med 8 (2011), 23–31.
23. Greenblatt, D.J., von Moltke, L.L., Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs. J Clin Pharmacol 48 (2008), 1350–1355.
24. Paine, M.F., Ludington, S.S., Chen, M.L., Stewart, P.W., Huang, S.M., Watkins, P.B., Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?. Drug Metab Dispos 33 (2005), 426–433.
25. Kim, R.B., Leake, B.F., Choo, E.F., et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70 (2001), 189–199.
26. Schmucker, D.L., Woodhouse, K.W., Wang, R.K., et al. Effects of age and gender on in vitro properties of human liver microsomal monooxygenases. Clin Pharmacol Ther 48 (1990), 365–374.
27. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., Guengerich, F.P., Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270 (1994), 414–423.
28. George, J., Byth, K., Farrell, G.C., Age but not gender selectively affects expression of individual cytochrome P450 proteins in human liver. Biochem Pharmacol 50 (1995), 727–730.
29. Hunt, C.M., Westerkam, W.R., Stave, G.M., Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol 44 (1992), 275–283.
30. Wolbold, R., Klein, K., Burk, O., et al. Sex is a major determinant of CYP3A4 expression in human liver. Hepatology 38 (2003), 978–988.
31. Schuetz, E.G., Furuya, K.N., Schuetz, J.D., Interindividual variation in expression of P-glycoprotein in normal human liver and secondary hepatic neoplasms. J Pharmacol Exp Ther 275 (1995), 1011–1018.
32. Cummins, C.L., Wu, C.Y., Benet, L.Z., Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 72 (2002), 474–489.
33. Meibohm, B., Beierle, I., Derendorf, H., How important are gender differences in pharmacokinetics?. Clin Pharmacokinet 41 (2002), 329–342.
34. Venkataramanan, R., Starzl, T.E., Yang, S., et al. Biliary excretion of cyclosporine in liver transplant patients. Transplant Proc 17 (1985), 286–289.
35. Moller, A., Iwasaki, K., Kawamura, A., et al. The disposition of 14C-labeled tacrolimus after intravenous and oral administration in healthy human subjects. Drug Metab Dispos 27 (1999), 633–636.
36. Zimmerman, J.J., Exposure-response relationships and drug interactions of sirolimus. AAPS J 6 (2004), 1–12.
37. Kovarik, J.M., Hsu, C.H., McMahon, L., Berthier, S., Rordorf, C., Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications. Clin Pharmacol Ther 70 (2001), 247–254.
38. Moes, D.J., Press, R.R., den Hartigh, J., van der Straaten, T., de Fijter, J.W., Guchelaar, H.J., Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet 51 (2012), 467–480.
39. Patel, C.G., Ogasawara, K., Akhlaghi, F., Mycophenolic acid glucuronide is transported by multidrug resistance-associated protein 2 and this transport is not inhibited by cyclosporine, tacrolimus or sirolimus. Xenobiotica 43 (2013), 229–235.
40. Morissette, P., Albert, C., Busque, S., St-Louis, G., Vinet, B., In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit 23 (2001), 520–525.
41. van Hest, R.M., van Gelder, T., Vulto, A.G., Mathot, R.A., Population pharmacokinetics of mycophenolic acid in renal transplant recipients. Clin Pharmacokinet 44 (2005), 1083–1096.
42. Tornatore, K.M., Meaney, C.J., Wilding, G.E., et al. Influence of sex and race on mycophenolic acid pharmacokinetics in stable African American and Caucasian renal transplant recipients. Clin Pharmacokinet 54 (2015), 423–434.
43. Buckley, D.B., Klaassen, C.D., Tissue- and gender-specific mRNA expression of UDP-glucuronosyltransferases (UGTs) in mice. Drug Metab Dispos 35 (2007), 121–127.
44. Gallagher, C.J., Balliet, R.M., Sun, D., Chen, G., Lazarus, P., Sex differences in UDP-glucuronosyltransferase 2B17 expression and activity. Drug Metab Dispos 38 (2010), 2204–2209.
45. Suzuki, T., Zhao, Y.L., Nadai, M., et al. Gender-related differences in expression and function of hepatic P-glycoprotein and multidrug resistance-associated protein (Mrp2) in rats. Life Sci 79 (2006), 455–461.
46. Chen, S., Yueh, M.F., Evans, R.M., Tukey, R.H., Pregnane-x-receptor controls hepatic glucuronidation during pregnancy and neonatal development in humanized UGT1 mice. Hepatology 56 (2012), 658–667.
47. Anthony, M., Berg, M.J., Biologic and molecular mechanisms for sex differences in pharmacokinetics, pharmacodynamics, and pharmacogenetics: part I. J Womens Health Gend Based Med 11 (2002), 601–615.
48. Bergmann, T.K., Barraclough, K.A., Lee, K.J., Staatz, C.E., Clinical pharmacokinetics and pharmacodynamics of prednisolone and prednisone in solid organ transplantation. Clin Pharmacokinet 51 (2012), 711–741.
49. Potter, J.M., McWhinney, B.C., Sampson, L., Hickman, P.E., Area-under-the-curve monitoring of prednisolone for dose optimization in a stable renal transplant population. Ther Drug Monit 26 (2004), 408–414.
50. Magee, M.H., Blum, R.A., Lates, C.D., Jusko, W.J., Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol 41 (2001), 1180–1194.
51. Boekenoogen, S.J., Szefler, S.J., Jusko, W.J., Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab 56 (1983), 702–709.
52. Harris, R.Z., Tsunoda, S.M., Mroczkowski, P., Wong, H., Benet, L.Z., The effects of menopause and hormone replacement therapies on prednisolone and erythromycin pharmacokinetics. Clin Pharmacol Ther 59 (1996), 429–435.
53. Rohatagi, S., Hochhaus, G., Mollmann, H., Barth, J., Derendorf, H., Pharmacokinetic interaction between endogenous cortisol and exogenous corticosteroids. Pharmazie 50 (1995), 610–613.
54. Rosman, P.M., Benn, R., Kay, M., Wallace, E.Z., Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin. Nephron 37 (1984), 229–231.
55. Rosman, P.M., Benn, R., Kay, M., Tito, J., Wallace, E.Z., Cortisol binding in uremic plasma. I. Absence of abnormal cortisol binding to cortisol binding to corticosteroid-binding globulin. Nephron 37 (1984), 160–165.
56. Oelkers, W., Blumel, A., Schoneshofer, M., Schwartz, U., Hammerstein, J., Effects of ethinylestradiol on the renin-angiotensin-aldosterone-system and on plasma transcortin in women and men. J Clin Endocrinol Metab 43 (1976), 1036–1040.
57. Schlagenhauf, P., Chen, L.H., Wilson, M.E., et al. Sex and gender differences in travel-associated disease. Clin Infect Dis 50 (2010), 826–832.
58. Dogar, O.F., Shah, S.K., Chughtai, A.A., Qadeer, E., Gender disparity in tuberculosis cases in eastern and western provinces of Pakistan. BMC Infect Dis 12 (2012), 244–251.
59. Friedman, S.B., Grota, L.J., Glasgow, L.A., Differential susceptibility of male and female mice to encephalomyocarditis virus: effects of castration, adrenalectomy, and the administration of sex hormones. Infect Immun 5 (1972), 637–644.
60. Nicastri, E., Angeletti, C., Palmisano, L., et al. Gender differences in clinical progression of HIV-1-infected individuals during long-term highly active antiretroviral therapy. AIDS 19 (2005), 577–583.
61. Fish, E.N., The X-files in immunity: sex-based differences predispose immune responses. Nat Rev Immunol 8 (2008), 737–744.
62. Hirsch, H.H., BK virus: opportunity makes a pathogen. Clin Infect Dis 41 (2005), 354–360.
63. Hirsch, H.H., Randhawa, P., Practice ASTIDCo, BK polyomavirus in solid organ transplantation. Am J Transplant 13 (2013), 179–188.
64. Trofe, J., Gaber, L.W., Stratta, R.J., et al. Polyomavirus in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis 5 (2003), 21–28.
65. Ramos, E., Drachenberg, C.B., Papadimitriou, J.C., et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 13 (2002), 2145–2151.
66. Prince, O., Savic, S., Dickenmann, M., Steiger, J., Bubendorf, L., Mihatsch, M.J., Risk factors for polyoma virus nephropathy. Nephrol Dial Transplant 24 (2009), 1024–1033.
67. Rocha, P.N., Plumb, T.J., Miller, S.E., Howell, D.N., Smith, S.R., Risk factors for BK polyomavirus nephritis in renal allograft recipients. Clin Transplant 18 (2004), 456–462.
68. Howell, D.N., Smith, S.R., Butterly, D.W., et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 68 (1999), 1279–1288.
69. Randhawa, P.S., Finkelstein, S., Scantlebury, V., et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 67 (1999), 103–109.
70. Freeman, R.B., Paya, C., Pescovitz, M.D., et al. Risk factors for cytomegalovirus viremia and disease developing after prophylaxis in high-risk solid-organ transplant recipients. Transplantation 78 (2004), 1765–1773.
71. Kanter, J., Pallardo, L., Gavela, E., et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome. Transplant Proc 41 (2009), 2156–2158.
72. Cordero, E., Casasola, C., Ecarma, R., Danguilan, R., Cytomegalovirus disease in kidney transplant recipients: incidence, clinical profile, and risk factors. Transplant Proc 44 (2012), 694–700.
73. Jamal, A.J., Husain, S., Li, Y., Famure, O., Kim, S.J., Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients. Transplantation 97 (2014), 569–575.
74. Eitner, F., Hauser, I.A., Rettkowski, O., et al. Risk factors for pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients. Nephrol Dial Transplant 26 (2011), 2013–2017.
75. Radisic, M., Lattes, R., Chapman, J.F., et al. Risk factors for pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 5 (2003), 84–93.
76. Casimir, G.J., Duchateau, J., Gender differences in inflammatory processes could explain poorer prognosis for males. J Clin Microbiol 49 (2011), 478–479.
77. Jain, P.T., Gewirtz, D.A., Estradiol enhances gene delivery to human breast tumor cells. J Mol Med 76 (1998), 709–714.
78. Perrottet, N., Csajka, C., Pascual, M., et al. Population pharmacokinetics of ganciclovir in solid-organ transplant recipients receiving oral valganciclovir. Antimicrob Agents Chemother 53 (2009), 3017–3023.
79. Cerrutti, J.A., Brandoni, A., Quaglia, N.B., Torres, A.M., Sex differences in p-aminohippuric acid transport in rat kidney: role of membrane fluidity and expression of OAT1. Mol Cell Biochem 233 (2002), 175–179.
80. Ljubojevic, M., Herak-Kramberger, C.M., Hagos, Y., et al. Rat renal cortical OAT1 and OAT3 exhibit gender differences determined by both androgen stimulation and estrogen inhibition. Am J Physiol Renal Physiol 287 (2004), F124–F138.
81. van Kruijsdijk, R.C., Visseren, F.L., Ridker, P.M., et al. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women. Heart 101 (2015), 369–376.